|
 |
| home > epc > spring 2002 > maintaining validation control over edc systems during a clinical study |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
A lot has been written about the benefits of implementing electronic data capture (EDC) in the context of clinical studies. Topics commonly covered include the regulations, guidance and standards against which EDC solutions are created and implemented, the methods for maintaining data security, and those for measuring and delivering a return on investment, not to mention the general ways in which EDC affects and improves the processes of data gathering and what the future holds.
Despite the discussion about EDC there has been limited use of the technology throughout pharmaceutical companies' development pipelines. Whilst 50 per cent of companies may claim to have used EDC, this has commonly only been in pilot phase. This level of maturity is reflected in the industry estimates that EDC is still only used in between 5 per cent and 10 per cent of studies commenced on an annual basis (1).
Companies are grappling with the practical aspects of EDC implementation in a constantly changing environment. This situation presents particularly interesting challenges for the clinical research organisation (CRO) community. CROs find themselves either trying to implement a 'standard EDC solution' or deliver flexibility to their clients. Both approaches have their limiting factors. As the market matures, perhaps the latter approach best enables CROs to take advantage of the EDC technology which proves itself to satisfy the needs of their market segment.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Clinical Trials in CNS
25-26 November 2008, Copthorne Tara Hotel, London, UK
SMi present their 7th annual conference… Clinical Trials in CNS 25th to 26th November 2008, Copthorne Tara Hotel, London, UK
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
